March 30, 2021
Now available TRAZIMERA™ (trastuzumab-qyyp)
TRAZIMERA™ is a HER2/neu receptor antagonist indicated for:
- The treatment of HER2-overexpressing breast cancer.
- The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.